5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-3-tolyl)hydantoin profile

5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-3-tolyl)hydantoin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	129851
CHEMBL ID	4465426
SCHEMBL ID	1209011
MeSH ID	M0113570

Synonyms (25)

Synonym
2,4-imidazolidinedione, 3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethyl-
hydantoin, 5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-m-tolyl)-
3-(3-trifluormethyl-4-fluor-phenyl)-5,5-dimethyl-hydantoin [german]
5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-3-tolyl)hydantoin
5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluor-m-tolyl)hydantoin [german]
2,4-imidazolidinedione, 5,5-dimethyl-3-(4-fluoro-3-(trifluoromethyl)phenyl)-
5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-m-tolyl)hydantoin
brn 0820355
3-[4-fluoro-3-(trifluoromethyl)phenyl]-5,5-dimethylimidazolidine-2,4-dione
70842-04-5
5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluor-m-tolyl)hydantoin
3-(3-trifluormethyl-4-fluor-phenyl)-5,5-dimethyl-hydantoin
3-(4-fluoro-3-trifluoromethylphenyl)-5,5-dimethylimidazolidine-2,4-dione
SCHEMBL1209011
c12h10f4n2o2
ro 13-3978
AKOS027255824
AS-71927
CHEMBL4465426 ,
CS-0047525
3-(4-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethylimidazolidine-2,4-dione
DTXSID00991101
3-[4-fluoro-3-(trifluoromethyl)phenyl]-2-hydroxy-5,5-dimethyl-3,5-dihydro-4h-imidazol-4-one
W11309
bdbm50550380

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	4.4000	0.0000	0.8753	10.0000	AID1686675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID1686683	Antischistosomal activity against juvenile Schistosoma mansoni cercariae infected in mouse assessed as effective dose causing reduction in worm burden	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1532031	Antischistosomal activity against adult stage of Schistosoma mansoni infected in NMRI nude mouse administered as single oral dose on day 49 of post infection	2018	Bioorganic & medicinal chemistry letters, 12-15, Volume: 28, Issue:23-24	SAR of a new antischistosomal urea carboxylic acid.
AID1686675	Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686681	AUC (0 to last) in male Swiss mouse at 100 mg/kg, po administered via gavage measured upto 48 hrs postdose by LC-MS analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686676	Antischistosomal activity against Schistosoma mansoni infected in NMRI mouse assessed as reduction in total worm burden at 100 mg/kg, po administered as single dose starting on day 49 post-infection and measured at 28 days post treatment relative to contr	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686673	Intrinsic clearance in human liver microsome in presence of NADPH-regenerating system incubated over 60 mins by LC-MS analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686682	Antischistosomal activity against adult Schistosoma mansoni cercariae infected in mouse assessed as effective dose causing reduction in worm burden	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686672	Kinetic solubility of compound at pH 6.5 phosphate buffer by nephelometry	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686669	Octanol/water partition coefficient, logD of the compound at pH 7.4 by HPLC analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686674	Intrinsic clearance in mouse liver microsome in presence of NADPH-regenerating system incubated over 60 mins by LC-MS analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686670	Protein binding in immobilized human serum albumin by HPLC analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686677	Cytotoxicity against rat L6 cells assessed as reduction in cell viability at up to 30 uM	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686679	Cmax in male Swiss mouse at 100 mg/kg, po administered via gavage measured upto 48 hrs postdose by LC-MS analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686680	Tmax in male Swiss mouse at 100 mg/kg, po administered via gavage measured upto 48 hrs postdose by LC-MS analysis	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
AID1686671	Kinetic solubility of the compound in 0.01 M HCl at pH 2 by nephelometry	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (20.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
nilutamide [no description available]	2.52	2	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
praziquantel azinox: Russian drug	2.55	2	isoquinolines
hydantoins Hydantoins: Compounds based on imidazolidine dione. Some derivatives are ANTICONVULSANTS.. imidazolidine-2,4-dione : An imidazolidinone with oxo groups at position 2 and 4.	2.51	2	imidazolidine-2,4-dione
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.1	1	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
lucanthone hydrochloride Schistosomicides: Agents that act systemically to kill adult schistosomes.	2.4	2
imidazolidines [no description available]	2.1	1	azacycloalkane; imidazolidines; saturated organic heteromonocyclic parent

Condition	Relationship Strength	Studies
Bilharziasis [description not available]	2.13	1
Schistosomiasis Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.	2.13	1
Schistosoma mansoni Infection [description not available]	2.81	3
Schistosomiasis mansoni Schistosomiasis caused by Schistosoma mansoni. It is endemic in Africa, the Middle East, South America, and the Caribbean and affects mainly the bowel, spleen, and liver.	2.81	3
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.51	2
Fasciola Infection [description not available]	2.11	1
Echinostomiasis Infection by flukes of the genus Echinostoma.	2.11	1
Fascioliasis Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.	2.11	1

5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-3-tolyl)hydantoin

Description

Cross-References

Synonyms (25)

Protein Targets (1)

Inhibition Measurements

Biological Processes (56)

Molecular Functions (23)

Ceullar Components (8)

Bioassays (15)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.53

Study Types

5,5-dimethyl-3-(alpha,alpha,alpha,4-tetrafluoro-3-tolyl)hydantoin

Description

Cross-References

Synonyms (25)

Protein Targets (1)

Inhibition Measurements

Biological Processes (56)

Molecular Functions (23)

Ceullar Components (8)

Bioassays (15)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.53

Study Types

Related Drugs (6)

Related Conditions (8)